5 Aseptic Process Simulation Mistakes That Fail Media Fills

A media fill is meant to prove that your aseptic process can produce a sterile product. Too often it proves only that the media fill was easy to pass. That gap is where inspectors focus, and where EU GMP Annex 1 raises the bar. Here are five aseptic process simulation mistakes that quietly weaken the exercise.

1. Simulating the process you wish you ran

The media fill must reflect the real process, including its worst realistic conditions. Running it at maximum operator comfort, minimum interventions and pristine line conditions is not simulating manufacturing. Annex 1 expects the design to represent routine and worst-case activities, including the interventions that actually occur.

2. Under-representing interventions

Every routine and non-routine intervention that happens in production should be represented, at the frequency and difficulty they occur. If your shift includes stoppage clearances, component top-ups and environmental sampling, a media fill that skips them is not a valid model of risk.

3. Treating duration and unit count as a formality

The number of units and the fill duration should challenge the process, not just satisfy a minimum. A simulation that ends before the longest realistic campaign leaves the highest-risk window untested. Line speed, container size and hold times all need to reflect the hardest version of the real run.

4. Weak incubation and read discipline

A media fill is only as good as its incubation and inspection. Incubation conditions, temperatures and read timing should follow a defined, justified regime, and every unit must be accounted for. Missing or damaged units are not a rounding error. They are a data integrity question waiting to be asked.

5. Passing a media fill and ignoring the trend

A single passing run is a snapshot. The signal lives in the trend across fills, operators, shifts and lines. Reviewing each media fill in isolation misses the slow drift that a trend review would catch long before a contamination event.

Why open filling lines raise the stakes

On an open filling line the product is exposed to the room environment during critical steps, so the aseptic technique of the operator and the realism of the media fill carry more weight, not less. A low bioburden upstream process does not remove that exposure. This is why regulators treat the media fill on an open line as a direct test of contamination control, and why a simulation that softens the hardest interventions gives false assurance exactly where the risk is highest.

Designing a media fill that challenges the process

A defensible design starts from the real production record: the longest campaign, the full set of interventions and their true frequency, the shift changes, the line stoppages, and the operators who actually run the line. Build the worst realistic day, then justify every simplification in writing. If a challenge is left out, the protocol should say why. The goal is a simulation that would fail if the process would fail, because only that version protects the patient.

Frequently asked questions

What is a media fill in aseptic processing?

A media fill, or aseptic process simulation, replaces product with a sterile growth medium to demonstrate that the aseptic process can reliably produce a sterile unit under realistic conditions.

How often are media fills required under Annex 1?

Annex 1 expects simulations at defined intervals and for each shift and line configuration, with the design justified against routine and worst-case activities, and the exact frequency confirmed against your validated APS programme.

About the author

Kieran Falvey is Founder and Managing Director of Pharmalliance Consulting Ltd and the creator of Contamination Control by Design (CCbD). He has more than 20 years designing, building and running pharmaceutical facilities worldwide, across FDA, EMA, TGA, PIC/S and Indian FDA (CDSCO) jurisdictions. Global expert in cGMP Compliance, Remediation and Contamination Control, helping Sterile, Non-Sterile, ATMP and Cosmetic companies navigate cGMP compliance issues.

About Pharmalliance Consulting

Pharmalliance Consulting is a GMP compliance consultancy serving pharmaceutical, sterile, non-sterile, OSD, ATMP and cosmetic manufacturers in Ireland, the UK, the EU and the US. It helps sites identify and remediate GMP risks across facilities, quality systems and contamination control, aligned with HPRA, MHRA, EMA and FDA expectations, turning findings into defensible, inspection-ready practice.

Want your media fill and aseptic programme to reflect your hardest real day? Explore our Contamination Control by Design approach, or talk to the team about pressure-testing your APS design before your next campaign.